Adverse Events of Antimuscarinics for Treating Overactive Bladder
Author Information
Author(s): Kessler Thomas M., Bachmann Lucas M., Minder Christoph, Löhrer David, Umbehr Martin, Schünemann Holger J., Kessels Alfons G. H.
Primary Institution: Horten Centre for Patient Oriented Research, University of Zürich, Zürich, Switzerland
Hypothesis
The study aims to compare adverse events of antimuscarinics using a network meta-analytic approach.
Conclusion
Most currently used antimuscarinics seem to be equivalent first choice drugs to start the treatment of OAB except for oral oxybutynin dosages of ≥10 mg/d which may have more unfavorable adverse event profiles.
Supporting Evidence
- 69 trials enrolling 26,229 patients were included in the analysis.
- Similar overall adverse event profiles were found for most antimuscarinics except for orally administered oxybutynin.
- Gastrointestinal side effects were the most frequently reported adverse events.
- Age, gender, and duration of treatment had no significant influence on adverse events.
Takeaway
This study looked at different medications for overactive bladder and found that most of them are equally good, but one type, oxybutynin, can cause more problems if taken in higher doses.
Methodology
The study included a systematic review and network meta-analysis of randomized controlled trials comparing antimuscarinics for treating OAB.
Potential Biases
There is a potential risk of reporting bias due to variability in adverse event reporting over the years.
Limitations
The study did not account for differences in medication frequency and formulations, and the reporting of adverse events may have been inconsistent across trials.
Participant Demographics
The mean age of participants was 59 years, with 76% being female.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website